Higher peak expiratory flow associated with decreased headache risk in middle-aged and older adults
1. Higher peak expiratory flow was associated with a lower probability and lower risk of headache in middle-aged and older ...
Tag: pulmonology
GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors
1. GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. ...
FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis
Key Points: 1. First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data ...
Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
1. In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the forced vital ...
Nerandomilast slows FVC decline in progressive pulmonary fibrosis
1. In this randomized controlled trial, treatment with nerandomilast led to slower declines in forced vital capacity (FVC) in patients ...
Tumor-infiltrating clonal hematopoiesis is associated with NSCLC recurrence
1. In this retrospective cohort study, the presence of tumor-infiltrating clonal hematopoiesis (TI-CH) was associated with an increased risk of ...
Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
1. In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, sotatercept reduced ...
Mepolizumab decreases exacerbations in patients with eosinophilic COPD
1. In this randomized controlled trial, mepolizumab decreased the annualized rate of moderate or severe exacerbations when added to triple ...
Poor baseline lung function associated with increased risk of incident tuberculosis
1. The risk of tuberculosis (TB) was higher in individuals with obstructive or restrictive lung function impairment compared to those ...
Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule
Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial hypertension ...
